Cited 7 times in
Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이재승 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2021-04-29T16:46:32Z | - |
dc.date.available | 2021-04-29T16:46:32Z | - |
dc.date.issued | 2021-01 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/182011 | - |
dc.description.abstract | Purpose: Alpha-fetoprotein (AFP) is a prognostic marker for hepatocellular carcinoma (HCC). We investigated the prognostic value of AFP levels in patients who achieved complete response (CR) to transarterial chemoembolization (TACE) for HCC. Materials and methods: Between 2005 and 2018, 890 patients with HCC who achieved a CR to TACE were recruited. An AFP responder was defined as a patient who showed elevated levels of AFP (>10 ng/mL) during TACE, but showed normalization or a >50% reduction in AFP levels after achieving a CR. Results: Among the recruited patients, 569 (63.9%) with naïve HCC and 321 (36.1%) with recurrent HCC after complete resection were treated. Before TACE, 305 (34.3%) patients had multiple tumors, 219 (24.6%) had a maximal tumor size >3 cm, and 22 (2.5%) had portal vein tumor thrombosis. The median AFP level after achieving a CR was 6.36 ng/mL. After a CR, 473 (53.1%) patients experienced recurrence, and 417 (46.9%) died [median progression-free survival (PFS) and overall survival (OS) of 16.3 and 62.8 months, respectively]. High AFP levels at CR (>20 ng/mL) were independently associated with a shorter PFS [hazard ratio (HR)=1.403] and OS (HR=1.284), together with tumor multiplicity at TACE (HR=1.518 and 1.666, respectively). AFP non-responders at CR (76.2%, n=359 of 471) showed a shorter PFS (median 10.5 months vs. 15.5 months, HR=1.375) and OS (median 41.4 months vs. 61.8 months, HR=1.424) than AFP responders (all p=0.001). Conclusion: High AFP levels and AFP non-responders were independently associated with poor outcomes after TACE. AFP holds clinical implications for detailed risk stratification upon achieving a CR after TACE. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Arteries* | - |
dc.subject.MESH | Carcinoma, Hepatocellular / diagnosis | - |
dc.subject.MESH | Carcinoma, Hepatocellular / metabolism | - |
dc.subject.MESH | Carcinoma, Hepatocellular / therapy* | - |
dc.subject.MESH | Chemoembolization, Therapeutic* / adverse effects | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Neoplasms / diagnosis | - |
dc.subject.MESH | Liver Neoplasms / metabolism | - |
dc.subject.MESH | Liver Neoplasms / therapy* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | Recurrence | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Venous Thrombosis / etiology | - |
dc.subject.MESH | alpha-Fetoproteins / metabolism* | - |
dc.title | Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jae Seung Lee | - |
dc.contributor.googleauthor | Young Eun Chon | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Kwang Hyub Han | - |
dc.contributor.googleauthor | Wonseok Kang | - |
dc.contributor.googleauthor | Moon Seok Choi | - |
dc.contributor.googleauthor | Geum Youn Gwak | - |
dc.contributor.googleauthor | Yong Han Paik | - |
dc.contributor.googleauthor | Joon Hyeok Lee | - |
dc.contributor.googleauthor | Kwang Cheol Koh | - |
dc.contributor.googleauthor | Seung Woon Paik | - |
dc.contributor.googleauthor | Hwi Young Kim | - |
dc.contributor.googleauthor | Tae Hun Kim | - |
dc.contributor.googleauthor | Kwon Yoo | - |
dc.contributor.googleauthor | Yeonjung Ha | - |
dc.contributor.googleauthor | Mi Na Kim | - |
dc.contributor.googleauthor | Joo Ho Lee | - |
dc.contributor.googleauthor | Seong Gyu Hwang | - |
dc.contributor.googleauthor | Soon Sun Kim | - |
dc.contributor.googleauthor | Hyo Jung Cho | - |
dc.contributor.googleauthor | Jae Youn Cheong | - |
dc.contributor.googleauthor | Sung Won Cho | - |
dc.contributor.googleauthor | Seung Ha Park | - |
dc.contributor.googleauthor | Nae Yun Heo | - |
dc.contributor.googleauthor | Young Mi Hong | - |
dc.contributor.googleauthor | Ki Tae Yoon | - |
dc.contributor.googleauthor | Mong Cho | - |
dc.contributor.googleauthor | Jung Gil Park | - |
dc.contributor.googleauthor | Min Kyu Kang | - |
dc.contributor.googleauthor | Soo Young Park | - |
dc.contributor.googleauthor | Young Oh Kweon | - |
dc.contributor.googleauthor | Won Young Tak | - |
dc.contributor.googleauthor | Se Young Jang | - |
dc.contributor.googleauthor | Dong Hyun Sinn | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.identifier.doi | 10.3349/ymj.2021.62.1.12 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A05963 | - |
dc.contributor.localId | A04268 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 33381930 | - |
dc.subject.keyword | Carcinoma, hepatocellular | - |
dc.subject.keyword | alpha-fetoprotein | - |
dc.subject.keyword | prognosis | - |
dc.subject.keyword | transarterial chemoembolization | - |
dc.subject.keyword | treatment outcome | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 김범경 | - |
dc.contributor.affiliatedAuthor | 김승업 | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.contributor.affiliatedAuthor | 이재승 | - |
dc.contributor.affiliatedAuthor | 한광협 | - |
dc.citation.volume | 62 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 12 | - |
dc.citation.endPage | 20 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.62(1) : 12-20, 2021-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.